Published in PLoS One on August 23, 2010
Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS (2011) 1.22
Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother (2013) 1.16
SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One (2011) 1.01
A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo. Antimicrob Agents Chemother (2013) 0.95
Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Res (2011) 0.91
The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One (2013) 0.85
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials (2013) 0.83
Nanoparticle-based drug delivery to the vagina: a review. J Control Release (2014) 0.83
Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. PLoS One (2013) 0.82
Microbicides: a new hope for HIV prevention. Indian J Med Res (2011) 0.81
Polymeric drugs: Advances in the development of pharmacologically active polymers. J Control Release (2015) 0.81
Multivalent polymers for drug delivery and imaging: the challenges of conjugation. Biomacromolecules (2014) 0.80
Antiviral mechanism of polyanionic carbosilane dendrimers against HIV-1. Int J Nanomedicine (2016) 0.79
Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations. Nucleic Acids Res (2015) 0.79
Evaluation of the activity of new cationic carbosilane dendrimers on trophozoites and cysts of Acanthamoeba polyphaga. Parasitol Res (2014) 0.78
Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. HIV AIDS (Auckl) (2013) 0.77
The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials. Nanomedicine (Lond) (2015) 0.76
Particle-based technologies for osteoarthritis detection and therapy. Drug Deliv Transl Res (2016) 0.75
Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: mechanism of antiviral action. Int J Nanomedicine (2016) 0.75
Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine (2015) 0.75
N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine. J Acquir Immune Defic Syndr (2012) 0.75
Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal Immunol (2017) 0.75
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71
Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (2006) 10.56
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 7.93
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods (1988) 7.74
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet (2009) 6.80
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol (1995) 5.43
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev (2002) 5.29
Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol (2004) 3.92
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One (2008) 3.45
Microbicide drug candidates to prevent HIV infection. Lancet (2007) 3.06
Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol (2000) 2.97
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J Virol (1996) 2.75
The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A (2003) 2.43
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med (2007) 2.41
Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS (2007) 2.35
In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother (2004) 2.27
A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis (2005) 2.26
Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother (2007) 2.22
Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol (2002) 2.11
Enhancement of HIV infection by cellulose sulfate. AIDS Res Hum Retroviruses (2008) 2.04
Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis (2006) 2.01
Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother (1996) 1.86
Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis (2009) 1.81
The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med (2010) 1.76
Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother (2008) 1.68
SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses (2005) 1.63
Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother (2003) 1.59
Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology (2006) 1.58
Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol (2000) 1.55
Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm (2005) 1.53
Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother (2000) 1.49
A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis (2007) 1.48
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology (2007) 1.41
Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antiviral Res (2005) 1.37
Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother (2005) 1.31
The transmission of AIDS: the case of the infected cell. JAMA (1988) 1.27
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology (2007) 1.21
Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol Pharmacol (2000) 1.17
Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study. AIDS (2006) 1.16
Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci (2009) 1.11
A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis. J Acquir Immune Defic Syndr (2009) 1.03
The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antiviral Res (2009) 1.00
Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study. Sex Transm Dis (2010) 0.99
Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem (1995) 0.96
Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. J Infect Dis (1992) 0.95
Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. Antimicrob Agents Chemother (2009) 0.93
Dendrimers as therapeutic agents: a systematic review. J Pharm Pharmacol (2009) 0.88
Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition. Mol Pharm (2007) 0.86
Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. Mol Pharm (2006) 0.86
Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicides. Antimicrob Agents Chemother (2009) 0.81
Analogues and derivatives of tenoxicam. 1. Synthesis and antiinflammatory activity of analogues with different residues on the ring nitrogen and the amide nitrogen. J Med Chem (1987) 0.79
Mutations in both env and gag genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology. Antivir Chem Chemother (2005) 0.77
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
A cucurbituril-based gyroscane: a new supramolecular form. Angew Chem Int Ed Engl (2002) 3.95
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A (2007) 3.94
Reconciling reinforcement learning models with behavioral extinction and renewal: implications for addiction, relapse, and problem gambling. Psychol Rev (2007) 3.73
A unified framework for addiction: vulnerabilities in the decision process. Behav Brain Sci (2008) 2.83
Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol (2009) 2.49
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med (2007) 2.41
The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol (2007) 2.41
Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl (2008) 2.38
Partitioning and bioaccumulation of PBDEs and PCBs in Lake Michigan. Environ Sci Technol (2006) 2.29
Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol (2009) 2.14
The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A (2006) 2.13
Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci U S A (2009) 2.13
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol (2003) 2.07
Epidemic Lymphogranuloma venereum during epidemics of crack cocaine use and HIV infection in the Bahamas. Sex Transm Dis (2002) 1.79
Triple dissociation of information processing in dorsal striatum, ventral striatum, and hippocampus on a learned spatial decision task. Neuron (2010) 1.78
Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med (2012) 1.68
Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev (2011) 1.65
Cardiac-myocyte-specific excision of the vinculin gene disrupts cellular junctions, causing sudden death or dilated cardiomyopathy. Mol Cell Biol (2007) 1.63
Carbohydrate residues downstream of the terminal Galalpha(1,3)Gal epitope modulate the specificity of xenoreactive antibodies. Immunol Cell Biol (2007) 1.59
Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm (2005) 1.53
Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis (2010) 1.52
The Na+-Ca2+ exchanger is essential for the action of cardiac glycosides. Circ Res (2002) 1.52
An activation-specific platelet inhibitor that can be turned on/off by medically used hypothermia. Arterioscler Thromb Vasc Biol (2011) 1.46
Biophysics: is rhodopsin dimeric in native retinal rods? Nature (2003) 1.43
Challenges and advances in computational docking: 2009 in review. J Mol Recognit (2010) 1.42
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology (2007) 1.41
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res (2008) 1.40
Hippocampal sharp waves and reactivation during awake states depend on repeated sequential experience. J Neurosci (2006) 1.40
Altering mucus rheology to "solidify" human mucus at the nanoscale. PLoS One (2009) 1.37
Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antiviral Res (2005) 1.37
Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol (2006) 1.33
Mechanisms of HIV-1 neurotropism. Curr HIV Res (2006) 1.33
Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis (2010) 1.33
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine (2012) 1.30
Acquisition of methicillin-resistant Staphylococcus aureus in a large intensive care unit. Infect Control Hosp Epidemiol (2003) 1.28
Astrocyte specific viral strains in HIV dementia. Ann Neurol (2004) 1.26
Latest developments in molecular docking: 2010-2011 in review. J Mol Recognit (2013) 1.26
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog (2006) 1.25
CD16+ monocyte subset preferentially harbors HIV-1 and is expanded in pregnant Malawian women with Plasmodium falciparum malaria and HIV-1 infection. J Infect Dis (2007) 1.22
The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. Mol Pharm (2008) 1.21
Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer. J Virol (2005) 1.21
Knockout mice for pharmacological screening: testing the specificity of Na+-Ca2+ exchange inhibitors. Circ Res (2002) 1.20
Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J Virol (2006) 1.19
Low TRBP levels support an innate human immunodeficiency virus type 1 resistance in astrocytes by enhancing the PKR antiviral response. J Virol (2005) 1.17
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol (2011) 1.16
Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother (2013) 1.16
Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. Curr HIV Res (2005) 1.15
Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J Virol (2006) 1.11
Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors. J Med Chem (2012) 1.10
Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection. Retrovirology (2008) 1.10
Anti-sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. J Immunol (2002) 1.10
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology (2010) 1.08
Maturation of the HIV reverse transcription complex: putting the jigsaw together. Rev Med Virol (2009) 1.08
The packaging and maturation of the HIV-1 Pol proteins. Curr HIV Res (2005) 1.07
Regulation of CC chemokine receptor 5 and CD4 expression and human immunodeficiency virus type 1 replication in human macrophages and microglia by T helper type 2 cytokines. J Infect Dis (2002) 1.07
A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A (2003) 1.07
Decoding the membrane activity of the cyclotide kalata B1: the importance of phosphatidylethanolamine phospholipids and lipid organization on hemolytic and anti-HIV activities. J Biol Chem (2011) 1.06
Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol (2009) 1.06
HIV-1 infection induces changes in expression of cellular splicing factors that regulate alternative viral splicing and virus production in macrophages. Retrovirology (2008) 1.05
Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. Biochem J (2007) 1.05
Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv Mater (2012) 1.05
Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology (2008) 1.04
Myocardial function with reduced expression of the sodium-calcium exchanger. J Card Fail (2010) 1.03
A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis. J Acquir Immune Defic Syndr (2009) 1.03
Three-dimensional structures of carbohydrate determinants of Lewis system antigens: implications for effective antibody targeting of cancer. Immunol Cell Biol (2005) 1.03
Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure. J Virol (2004) 1.02
SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One (2011) 1.01
Discovery of retroviral homologs in bats: implications for the origin of mammalian gammaretroviruses. J Virol (2012) 1.00
Bioinformatic prediction programs underestimate the frequency of CXCR4 usage by R5X4 HIV type 1 in brain and other tissues. AIDS Res Hum Retroviruses (2008) 1.00
Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem (2007) 1.00
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology (2011) 1.00
Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. J Infect Dis (2004) 1.00